SCHEDULE: Great Point Partners Discloses 8.45% Stake in Sol-Gel

Great Point Partners, LLC and its principals have disclosed a beneficial ownership of 8.45% in Sol-Gel Technologies Ltd. ordinary shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively beneficially own 274,363 ordinary shares of Sol-Gel Technologies Ltd.
• This ownership represents 8.45% of Sol-Gel Technologies Ltd.'s outstanding ordinary shares.
• The percentage is based on 3,245,270 shares outstanding, as reported by Sol-Gel Technologies Ltd. in its 424B Prospectus filed on March 24, 2026.
• The shares are held by Biomedical Value Fund, L.P. (181,078 shares) and Biomedical Offshore Value Fund, Ltd. (93,285 shares), for which Great Point Partners, LLC acts as investment manager.
• Dr. Jeffrey R. Jay, M.D., as Senior Managing Member, and Ms. Lillian Nordahl, as Managing Director of Great Point Partners, LLC, have shared voting and investment power over these shares.
• The reporting persons disclaim beneficial ownership except to the extent of their respective pecuniary interests.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institutional investor can signal confidence in the company's long-term value, even if the filing itself is a routine disclosure.

Positives

• A significant institutional investor, Great Point Partners, LLC, has disclosed a substantial stake, potentially signaling confidence in Sol-Gel Technologies Ltd.
• The filing indicates a passive investment intent, as certified by the reporting persons, stating the securities were not acquired for the purpose of changing or influencing control.

Risks

• The concentration of 8.45% of shares under the shared voting and dispositive power of Great Point Partners, LLC and its principals could represent a degree of influence, even if stated as passive, which might impact other shareholders.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a specialized healthcare investment firm like Great Point Partners in a biotechnology or pharmaceutical company such as Sol-Gel Technologies Ltd. often draws attention from other investors. Such a move can be interpreted as a vote of confidence in the company's pipeline, market position, or future prospects, potentially influencing market perception and trading activity within the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may increase investor confidence and potentially attract further institutional interest.
• Company Management: Awareness of a large, potentially influential shareholder may impact strategic decisions, even if the stated intent is passive.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which can be a positive signal. However, as a Schedule 13G, it primarily discloses ownership and does not provide new operational or financial performance data. Without additional information on Sol-Gel Technologies Ltd.'s fundamentals or strategic direction, a 'hold' recommendation is prudent, acknowledging the institutional confidence while awaiting further catalysts or financial updates.

Keywords

Sol-Gel Technologies, Great Point Partners, Beneficial Ownership, Schedule 13G, M8694L137, Ordinary Shares, Institutional Investor, Biomedical Value Fund, Biomedical Offshore Value Fund